These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26746169)

  • 61. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.
    Costello SP; Soo W; Bryant RV; Jairath V; Hart AL; Andrews JM
    Aliment Pharmacol Ther; 2017 Aug; 46(3):213-224. PubMed ID: 28612983
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Khan KJ; Ullman TA; Ford AC; Abreu MT; Abadir A; Marshall JK; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):661-73. PubMed ID: 21407187
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials.
    Shen J; Zuo ZX; Mao AP
    Inflamm Bowel Dis; 2014 Jan; 20(1):21-35. PubMed ID: 24280877
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis.
    Magro F; Estevinho MM; Dias CC; Correia L; Lago P; Ministro P; Portela F; Feakins R; Danese S; Peyrin-Biroulet L
    J Crohns Colitis; 2021 Apr; 15(4):551-566. PubMed ID: 32898223
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies.
    Bahnam P; Hanzel J; Ma C; Zou L; Narula N; Singh S; Kahan B; Jairath V
    J Crohns Colitis; 2023 Apr; 17(3):404-417. PubMed ID: 36219564
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review.
    Simadibrata M; Halimkesuma CC; Suwita BM
    Acta Med Indones; 2017 Oct; 49(4):363-368. PubMed ID: 29348389
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis.
    Vuyyuru SK; Nguyen TM; Hogan M; Raine T; Noor NM; Narula N; Verstockt B; Feagan BG; Singh S; Ma C; Jairath V
    Inflamm Bowel Dis; 2024 Apr; 30(4):651-659. PubMed ID: 37002875
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis.
    Sang LX; Chang B; Zhang WL; Wu XM; Li XH; Jiang M
    World J Gastroenterol; 2010 Apr; 16(15):1908-15. PubMed ID: 20397271
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.
    Suilik HA; Jaber F; Abuelazm M; Ramadan A; Elzeftawy MA; Elrosasy A; Youssef RA; Abdelazeem B; Hashash JG; Farraye FA; Ghoz H
    Inflamm Res; 2024 Feb; 73(2):183-198. PubMed ID: 38153524
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
    Jairath V; Khanna R; Zou GY; Stitt L; Mosli M; Vandervoort MK; D'Haens G; Sandborn WJ; Feagan BG; Levesque BG
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1200-10. PubMed ID: 26388424
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quantification of the placebo response in ulcerative colitis.
    Ilnyckyj A; Shanahan F; Anton PA; Cheang M; Bernstein CN
    Gastroenterology; 1997 Jun; 112(6):1854-8. PubMed ID: 9178676
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis.
    Ford AC; Luthra P; Hanauer SB; Travis SP; Harris MS; Reinisch W
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):1981-90. PubMed ID: 25218669
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Drug therapies for ulcerative proctitis: systematic review and meta-analysis.
    Lie MR; Kanis SL; Hansen BE; van der Woude CJ
    Inflamm Bowel Dis; 2014 Nov; 20(11):2157-78. PubMed ID: 25072502
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Hanzel J; Solitano V; Zou L; Zou GY; Peyrin-Biroulet L; Danese S; Singh S; Ma C; Wils P; Jairath V
    Clin Transl Gastroenterol; 2023 Nov; 14(11):e00629. PubMed ID: 37578211
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis.
    Kawakatsu S; Zhu R; Zhang W; Tang MT; Lu T; Quartino AL; Kågedal M
    J Pharmacokinet Pharmacodyn; 2022 Apr; 49(2):179-190. PubMed ID: 34657238
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies.
    Macaluso FS; Maida M; Ventimiglia M; Orlando A
    Dig Liver Dis; 2022 Feb; 54(2):183-191. PubMed ID: 34011482
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score.
    Moein A; Langenhorst J; Plan EL; Jin JY; Kågedal M; Kassir N
    Clin Transl Sci; 2023 Nov; 16(11):2310-2322. PubMed ID: 37718498
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis: a protocol of systematic review and meta-analysis of placebo-controlled, randomised clinical trials.
    Qin X; Wang M; Zhang W; Liu W; Shu H; Xiong X
    BMJ Open; 2024 Jan; 14(1):e076570. PubMed ID: 38267240
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.